Veracyte, Inc. (VCYT): who owns it and who trades it
As of Nov 16, 2026, VCYT insiders reported 50 open-market sales worth $19.2M and no purchases in the last 12 months, with 94% of the sale value made under pre-set 10b5-1 plans. The largest seller was Marc Stapley (CEO), with $8.9M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Veracyte
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns VCYT
367 funds and institutions reported VCYT shares worth $5.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 16.9%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 13.49M | 16.90% | $792M | +2% |
| FMR LLC (Fidelity) | 7.70M | 9.65% | $452M | -1% |
| Artisan Partners Limited Partnership | 5.54M | 6.94% | $325M | +1% |
| Vanguard Portfolio Management LLC | 4.72M | 5.91% | $277M | +6% |
| State Street Corp | 4.70M | 5.89% | $276M | -7% |
| Vanguard Capital Management LLC | 3.59M | 4.50% | $211M | +2% |
| Dimensional Fund Advisors LP | 2.83M | 3.54% | $166M | -2% |
| First Trust Advisors LP | 2.51M | 3.14% | $147M | +18% |
| ARK Investment Management LLC | 2.30M | 2.88% | $135M | -25% |
| Wellington Management Group LLP | 2.27M | 2.85% | $134M | -11% |
| Geode Capital Management, LLC | 2.10M | 2.64% | $124M | +8% |
| Goldman Sachs Group Inc | 1.64M | 2.06% | $96.5M | +29% |
| Fuller & Thaler Asset Management, Inc. | 1.51M | 1.89% | $88.7M | +7% |
| William Blair Investment Management, LLC | 1.43M | 1.79% | $84.1M | +45% |
| GW&K Investment Management, LLC | 1.42M | 1.78% | $83.2M | -1% |
| Morgan Stanley | 1.19M | 1.49% | $70M | +49% |
| Bank of America Corp | 1.10M | 1.38% | $64.7M | -24% |
| Driehaus Capital Management LLC | 1.05M | 1.31% | $61.4M | – |
| Northern Trust Corp | 996,154 | 1.25% | $58.5M | +7% |
| Charles Schwab Investment Management Inc | 939,983 | 1.18% | $55.2M | +2% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, VCYT insiders reported $0 of open-market purchases and $19.2M of sales. 94% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 27, 2026 | Karin Eastham | Director | Sale plan | 14,850 | $50.00 | $743K | Form 4 |
| Oct 27, 2026 | Jens Holstein | Director | Sale plan | 7,500 | $50.00 | $375K | Form 4 |
| Oct 19, 2026 | Muna Bhanji | Director | Sale plan | 1,864 | $43.70 | $81.5K | Form 4 |
| Sep 24, 2026 | Jens Holstein | Director | Sale plan | 7,500 | $47.00 | $352K | Form 4 |
| Sep 21, 2026 | John Leite | Global Chief Commercial | Sale plan | 4,015 | $40.00 | $161K | Form 4 |
| Sep 14, 2026 | Jens Holstein | Director | Sale plan | 5,000 | $40.95 | $205K | Form 4 |
| Sep 4, 2026 | Phillip G. Febbo | Chief Scientific & Med O | Sale plan | 10,405 | $42.89 | $446K | Form 4 |
| Sep 4, 2026 | Phillip G. Febbo | Chief Scientific & Med O | Sale plan | 2,705 | $43.66 | $118K | Form 4 |
| Sep 4, 2026 | Rebecca Chambers | CFO | Sale plan | 1,175 | $43.71 | $51.4K | Form 4 |
| Sep 4, 2026 | Rebecca Chambers | CFO | Sale plan | 2,477 | $42.81 | $106K | Form 4 |
| Sep 4, 2026 | Annie McGuire | Vice president | Sale plan | 1,100 | $43.67 | $48K | Form 4 |
| Sep 4, 2026 | Annie McGuire | Vice president | Sale plan | 2,154 | $42.79 | $92.2K | Form 4 |
| Sep 1, 2026 | Muna Bhanji | Director | Sale plan | 1,864 | $42.97 | $80.1K | Form 4 |
| Jun 18, 2026 | Karin Eastham | Director | Sale plan | 3,200 | $52.78 | $169K | Form 4 |
| Jun 18, 2026 | Karin Eastham | Director | Sale plan | 529 | $53.55 | $28.3K | Form 4 |
| Jun 4, 2026 | Annie McGuire | Vice president | Sale plan | 1,776 | $50.12 | $89K | Form 4 |
| Jun 4, 2026 | Annie McGuire | Vice president | Sale plan | 1,400 | $49.31 | $69K | Form 4 |
| Jun 4, 2026 | Rebecca Chambers | CFO | Sale plan | 1,600 | $49.28 | $78.8K | Form 4 |
| Jun 4, 2026 | Rebecca Chambers | CFO | Sale plan | 1,961 | $50.09 | $98.2K | Form 4 |
| Jun 4, 2026 | Marc Stapley | CEO | Sale plan | 138,051 | $50.12 | $6.9M | Form 4 |
| Jun 4, 2026 | John Leite | Global Chief Commercial | Sale plan | 13,975 | $50.07 | $700K | Form 4 |
| May 22, 2026 | Jonathan Wygant | Vice president | Sale | 24,000 | $45.40 | $1.1M | Form 4 |
| May 20, 2026 | Robert S Epstein | Director | Sale plan | 10,000 | $44.01 | $440K | Form 4 |
| May 6, 2026 | Annie McGuire | Vice president | Sale plan | 5,102 | $38.05 | $194K | Form 4 |
| May 6, 2026 | Annie McGuire | Vice president | Sale plan | 5,102 | $40.00 | $204K | Form 4 |
| Mar 4, 2026 | Rebecca Chambers | CFO | Sale plan | 13,941 | $36.33 | $506K | Form 4 |
| Mar 4, 2026 | Rebecca Chambers | CFO | Sale plan | 4,400 | $35.55 | $156K | Form 4 |
| Mar 4, 2026 | Marc Stapley | CEO | Sale plan | 26,279 | $36.28 | $953K | Form 4 |
| Mar 4, 2026 | Marc Stapley | CEO | Sale plan | 19,244 | $35.56 | $684K | Form 4 |
| Mar 4, 2026 | John Leite | Chief Commercial Officer | Sale plan | 5,260 | $35.19 | $185K | Form 4 |
| Mar 4, 2026 | Annie McGuire | Vice president | Sale plan | 4,994 | $35.29 | $176K | Form 4 |
| Mar 4, 2026 | Annie McGuire | Vice president | Sale plan | 1,664 | $36.34 | $60.5K | Form 4 |
| Mar 2, 2026 | Phillip G. Febbo | Chief Scientific & Med O | Sale plan | 13,425 | $36.16 | $485K | Form 4 |
| Dec 16, 2025 | Annie McGuire | Vice president | Sale plan | 10,639 | $43.13 | $459K | Form 4 |
| Dec 16, 2025 | Annie McGuire | Vice president | Sale plan | 100 | $43.68 | $4.4K | Form 4 |
| Dec 5, 2025 | Karin Eastham | Director | Sale plan | 800 | $46.59 | $37.3K | Form 4 |
| Dec 5, 2025 | Karin Eastham | Director | Sale plan | 12,808 | $45.84 | $587K | Form 4 |
| Dec 5, 2025 | Karin Eastham | Director | Sale plan | 6,392 | $44.52 | $285K | Form 4 |
| Dec 4, 2025 | Annie McGuire | Vice president | Sale plan | 720 | $47.10 | $33.9K | Form 4 |
| Dec 4, 2025 | Annie McGuire | Vice president | Sale plan | 702 | $47.51 | $33.4K | Form 4 |
| Dec 4, 2025 | Rebecca Chambers | CFO | Sale plan | 4,741 | $47.25 | $224K | Form 4 |
| Dec 4, 2025 | Rebecca Chambers | CFO | Sale plan | 8,537 | $46.61 | $398K | Form 4 |
| Dec 4, 2025 | Marc Stapley | CEO | Sale plan | 4,448 | $46.90 | $209K | Form 4 |
| Dec 4, 2025 | Marc Stapley | CEO | Sale plan | 3,220 | $47.35 | $152K | Form 4 |
| Dec 4, 2025 | John Leite | Chief Commercial Officer | Sale plan | 1,278 | $47.51 | $60.7K | Form 4 |
| Nov 25, 2025 | John Leite | Chief Commercial Officer | Sale plan | 2,808 | $50.00 | $140K | Form 4 |
| Nov 25, 2025 | Evan/ Fa Jones | Director | Sale plan | 1,106 | $50.25 | $55.6K | Form 4 |
| Nov 20, 2025 | Jens Holstein | Director | Sale plan | 7,049 | $42.48 | $299K | Form 4 |
| Nov 20, 2025 | Jens Holstein | Director | Sale plan | 1,491 | $40.95 | $61.1K | Form 4 |
| Nov 20, 2025 | Jens Holstein | Director | Sale plan | 1,460 | $43.21 | $63.1K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Marc Stapley | Chief Executive Officer, Director | – | $8.9M | Jun 4, 2026 |
| Karin Eastham | Director | – | $1.8M | Oct 27, 2026 |
| Rebecca Chambers | Chief Financial Officer | – | $1.6M | Sep 4, 2026 |
| Annie McGuire | SVP, General Counsel | – | $1.5M | Sep 4, 2026 |
| Jens Holstein | Director | – | $1.4M | Oct 27, 2026 |
| John Leite | Chief Commercial Officer-CLIA | – | $1.2M | Sep 21, 2026 |
| Jonathan Wygant | VP, Chief Accounting Officer | – | $1.1M | May 22, 2026 |
| Phillip G. Febbo | Chief Scientific & Med Officer | – | $1M | Sep 4, 2026 |
| Robert S Epstein | Director | – | $440K | May 20, 2026 |
| Muna Bhanji | Director | – | $162K | Oct 19, 2026 |
| Evan/ Fa Jones | Director | – | $55.6K | Nov 25, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
VCYT short interest
High short interest. 11.8% of VCYT shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 11%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 9.56M VCYT shares were sold short, 11.8% of the shares outstanding, down 2.7% from the report before. At the average daily volume of 1.16M shares, buying them all back would take about 8.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 9.56M | 11.85% | -3% | 1.16M | 8.2 |
| Oct 15, 2026 | 9.82M | 12.22% | -4% | 1.16M | 8.5 |
| Sep 30, 2026 | 10.18M | 12.66% | +21% | 1.73M | 5.9 |
| Sep 15, 2026 | 8.40M | 10.45% | +4% | 1.08M | 7.8 |
| Aug 31, 2026 | 8.08M | 10.05% | +19% | 1.38M | 5.8 |
| Aug 14, 2026 | 6.79M | 8.45% | -1% | 1.21M | 5.6 |
| Jul 31, 2026 | 6.86M | 8.53% | +3% | 1.43M | 4.8 |
| Jul 15, 2026 | 6.67M | 8.36% | -1% | 988,654 | 6.8 |
| Jun 30, 2026 | 6.72M | 8.42% | -21% | 1.77M | 3.8 |
| Jun 15, 2026 | 8.49M | 10.64% | +15% | 1.31M | 6.5 |
| May 29, 2026 | 7.35M | 9.21% | -14% | 1.14M | 6.5 |
| May 15, 2026 | 8.59M | 10.77% | +25% | 1.19M | 7.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded VCYT
Since Nov 17, 2024, 1 member of Congress reported 2 purchases and 1 sale of VCYT. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Mar 3, 2026, reported Apr 7, 2026.
Purchases 2Sales 1
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Apr 7, 2026 | Report |
| Nov 12, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Dec 15, 2025 | Report |
| Jun 16, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Jul 10, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Veracyte company events
Veracyte filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026AnnouncementThe Company announced the commencement of a share repurchase program previously authorized by the Board of Directors of the Company, pursuant to which the Company may repurchase up to $100.0 million of its outstanding common stock during the one-year period beginning on the date of the public… Filing
- Sep 14, 2026DealVeracyte completed its acquisition of Convergent pursuant to the terms of the Merger Agreement. Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- Jun 11, 2026LeadershipAs further described in Item 5.07 to this Current Report on Form 8-K (this “Report”), on June 10, 2026, at the 2026 Annual Meeting of Stockholders of Veracyte, Inc., the Company’s stockholders approved an amendment to the Company’s 2023 Equity Incentive Plan to increase the number of shares of the… Filing
- May 5, 2026ResultsReleased financial results. Filing
- Mar 16, 2026LeadershipVeracyte, Inc. announced the appointment of Dr. Kevin Haas, 40, as its Chief Development and Technology Officer, effective March 24, 2026. Filing
- Feb 25, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Veracyte financials
Famous investors that hold VCYT
5 of the 50 well-known investors we track reported holding VCYT in their latest 13F filing. The largest position is Cathie Wood's, worth $136M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Cathie Wood · ARK Investment Management | Q3 2026 | 2.96M | $136M | 0.8% | +29% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 682,711 | $31.4M | 0.0% | -3% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 93,410 | $4.3M | 0.0% | New |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 55,339 | $2.5M | 0.0% | -5% |
| Israel Englander · Millennium Management | Q3 2026 | 10,446 | $481K | 0.0% | -85% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named VCYT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 12, 2026 | Artisan Partners Asset Management Inc. | 13G/A | 2.9% |
| Nov 12, 2026 | Artisan Partners Asset Management Inc. | 13G/A | 2.9% |
| Nov 5, 2026 | FMR LLC | 13G/A | 7.7% |
| Nov 5, 2026 | FMR LLC | 13G/A | 7.7% |
Questions about Veracyte, Inc. (VCYT) stock
Who owns the most VCYT stock?
The largest reported owner of Veracyte, Inc. (VCYT) is BlackRock, Inc., with 16.9% of the company. In total, 367 funds and institutions reported holding VCYT at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are VCYT insiders buying or selling?
In the last 12 months, VCYT insiders reported no open-market purchases and 50 sales worth $19.2M. The latest trade was on Oct 27, 2026. See every trade.
What is the short interest in VCYT?
As of Oct 30, 2026, 9.56M VCYT shares were sold short, 11.8% of the shares outstanding, down 2.7% from the report before. At the average daily volume of 1.16M shares, buying them all back would take about 8.2 trading days (days to cover). See the history.
Have members of Congress traded VCYT?
Yes. 1 member of Congress reported 2 purchases and 1 sale of VCYT since Nov 17, 2024. The latest was reported on Apr 7, 2026. See the trades.
Which famous investors hold VCYT?
5 of the 50 well-known investors we track reported VCYT in their latest 13F filing, including Cathie Wood, Ken Fisher, Ken Griffin. The largest position is worth $136M. See all holders.
Executive pay
Veracyte's chief executive was paid a total of $7.4M for the year ended Dec 31, 2025. In the last 12 months, Veracyte's executives and directors bought no stock on the open market and sold $19.2M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.